Frontiers in Anti-Cancer Drug Discovery is a book series devoted to publishing the latest advances in anti-cancer drug design and discovery. In each volume, eminent scientists contribute reviews relevant to all areas of rational drug design and drug discovery including medicinal chemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, recent important patents, and structure-activity relationships. The book series should prove to be of interest to all pharmaceutical scientists involved in research in anti-cancer drug design and discovery. The book series is essential reading to all scientists involved in drug design and discovery who wish to keep abreast of rapid and important developments in the field.
This volume of the series focuses on reviews of treatments derived from natural sources (cannabinoid-based medicines and turmeric), immunotherapy, biomarkers for glioblastoma and some new drug targets for anti-cancer treatment.
The reviews included in this volume are:
- Cannabinoid-Based Anticancer Strategies
- The Beneficial Effects of Turmeric and Its Active Constituent in Cancer Treatment
- Immunotherapy Approaches Focusing on Cancer Stem Cells
- Immunotherapy for the Treatment of Hepatocellular Carcinoma
- Role of Biomarkers in Developing Therapies for Glioblastoma Multiforme
- Poly (ADP-ribose) Polymerases as New Drug Targets in Cancer Treatment
Table of Contents
Chapter 1 Cannabinoid-Based Anti-Cancer Strategies: Slowly Approaching the Bedside- Paula Morales and Nadine Jagerovic
- Introduction
- Palliative Effects
- Antitumor Properties
- Ecs Regulation in Cancer Tissue
- Molecular Basis for Cannabinoid Antitumor Actions
- Antiproliferative and Pro-Apoptotic Effects
- Effects on Tumor Invasion, Metastasis and Angiogenesis
- Towards Clinical Antitumor Application
- Antitumor Cannabinoids
- Endocannabinoids and Endocannabinoid-Like Synthetic Derivatives
- Phytocannabinoids and Phytocannabinoid-Like Synthetic Derivatives
- Synthetic Cannabinoids
- Aminoalkylindoles
- Arylpyrazoles
- Cannabinoid Quinones
- Other Antitumor Cannabinergic Ligands
- Conclusion and Future Prospects
- Consent for Publication
- Conflict of Interest
- Acknowledgements
- References
Chapter 2 The Beneficial Effects of Turmeric and Its Active
- Constituent in Cancer Treatment: Current and Future Trends
- Giftson J. Senapathy, Blassan P. George and Heidi Abrahamse
- Introduction
- Phytochemistry of Curcumin
- Structure Activity Relationship
- Pharmacological Properties of Curcumin
- Antioxidant and Prooxidant Nature of Curcumin
- Anticancer Activity of Curcumin
- Genitourinary Cancer
- Lung Cancer
- Breast Cancer
- Melanoma
- Ovarian Cancer
- Cervical Cancer
- Brain Tumor
- Prostate Cancer
- Head and Neck Cancer
- Gastro Intestinal Cancer
- Mode of Action of Curcumin
- Effect of Curcumin on Cancer Signaling Pathways
- Combination Therapies of Curcumin with Other Drugs
- Curcumin Analogs and Cancer Stem Cells
- Challenges in Turmeric and Curcumin Treatments
- Future Prospects
- Concluding Remarks
- Consent for Publication
- Conflict of Interest
- Acknowledgements
- References
Chapter 3 Immunotherapy Approaches Focusing on Cancer Stem Cells
- Marcela Rodrigues De Camargo, Rafael Carneiro Ortiz, Carolina Mendonça
- Gorgulho, Vanessa Soares Lara and Camila Oliveira Rodini
- Introduction
- Stem Cells
- Cancer Stem Cells
- Cancer Immunotherapy
- Cancer Stem Cell-Based Immunotherapy
- Conclusion
- Consent for Publication
- Conflict of Interest
- Acknowledgements
- List of Abbreviation
- References
Chapter 4 Immunotherapy for the Treatment of Hepatocellular
- Carcinoma
- Stepan M. Esagian, Ioannis A. Ziogas and Georgios Tsoulfas
- Introduction
- Epidemiology
- Management
- Early and Intermediate Hepatocellular Carcinoma
- Advanced Hepatocellular Carcinoma Management
- Sorafenib and Other Targeted Molecular Agents
- Immunotherapy
- History
- Immunotherapy in the Context of Hepatocellular Carcinoma
- Mechanisms of Action
- Immune Checkpoints and Cancer Immunoediting
- The Pd-1/Pd-L1 Pathway
- The Ctla-4 Pathway
- Combination to Enhance Anti-Tumor Immune Responses
- Fda-Approved Immunotherapy Regimens for Hcc
- Single-Agent Immune Checkpoint Inhibitors
- Nivolumab
- Pembrolizumab
- Double Immune Checkpoint Inhibitor Combination
- Nivolumab and Ipilimumab
- Immune Checkpoint Inhibitor and Anti-Vegf Monoclonal Antibody Combination
- Atezolizumab and Bevacizumab
- Non-Fda Approved Immunotherapy Under Investigation
- Single-Agent Immune Checkpoint Inhibitors
- Tislelizumab
- Camrelizumab
- Durvalumab
- Tremelimumab
- Atezolizumab
- Immune Checkpoint Inhibitor and Tyrosine Kinase Inhibitor Combination
- Pembrolizumab and Lenvatinib
- Atezolizumab and Cabozantinib
- Avelumab and Axitinib
- Camrelizumab and Apatinib
- Immune Checkpoint Inhibitor and Anti-Vegf Monoclonal Antibody Combination
- Durvalumab and Ramucirumab
- Double Immune Checkpoint Inhibitor Combination
- Tremelimumab and Durvalumab
- Immune Checkpoint Inhibitor and Locoregional Therapy Combination
- Tremelimumab and Ablation
- Immunotherapy in the Setting of Liver Transplantation
- Conclusion
- Consent for Publication
- Conflict of Interest
- Acknowledgements
- References
Chapter 5 Role of Biomarkers in Developing Therapies for Glioblastoma Multiforme
- Vijeta Prakash and Reema Gabrani
- Introduction
- Biomarkers in Molecular and Metabolic Pathways
- Epidermal Growth Factor Receptor
- Mgmt
- Tumor Protein P53
- Isocitrate Dehydrogenase
- Voltage-Dependent Anion Channel
- Micro Rna Biomarkers
- Gbm Cancer Stem Cells as Biomarker Based Therapy
- Imaging Modalities as Biomarker
- Immune Checkpoint as Biomarker
- Programmed Cell Death Ligand
- Cxcr4
- Adamtsl4
- Cavin1
- Heat Shock Protein-70
- Conclusion
- Abbreviations
- Consent for Publication
- Conflict of Interest
- Acknowledgements
- References
Chapter 6 Poly (Adp-Ribose) Polymerases as New Drug Targets in Cancer Treatment
- Fatih Tok and Bedia Koçyiğit-Kaymakçıoğlu
- Introduction
- Mechanisms of Dna Damage and Repair
- Parp Inhibitors and Their Mechanisms of Action
- Development and Clinical Trials of Parp Inhibitors in Cancer Treatment
- Recent Advances with Parp Inhibitor Research
- Conclusion
- Consent for Publication
- Conflict of Interest
- Acknowledgements
- References
Author
- Atta-ur-Rahman
- M. Iqbal Choudhary
